| 7.58 -0.15 (-1.94%) | 05-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.56 |
1-year : | 11.65 |
| Resists | First : | 9.04 |
Second : | 9.97 |
| Pivot price | 8.31 |
|||
| Supports | First : | 7.52 |
Second : | 6.26 |
| MAs | MA(5) : | 8 |
MA(20) : | 8.35 |
| MA(100) : | 8.29 |
MA(250) : | 14.92 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8 |
D(3) : | 17.8 |
| RSI | RSI(14): 38.1 |
|||
| 52-week | High : | 40.59 | Low : | 4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OTLK ] has closed above bottom band by 2.6%. Bollinger Bands are 39.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.88 - 7.95 | 7.95 - 8 |
| Low: | 7.37 - 7.46 | 7.46 - 7.52 |
| Close: | 7.47 - 7.63 | 7.63 - 7.72 |
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Fri, 10 May 2024
Outlook Therapeutics (OTLK) Scheduled to Post Earnings on Thursday - MarketBeat
Thu, 09 May 2024
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host ... - GlobeNewswire
Wed, 08 May 2024
Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Target Price at $46.43 - MarketBeat
Sun, 31 Mar 2024
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up (NASDAQ:OTLK) - Seeking Alpha
Fri, 22 Mar 2024
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD - Yahoo Finance
Tue, 12 Mar 2024
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 38.8 (%) |
| Held by Institutions | 24 (%) |
| Shares Short | 1,130 (K) |
| Shares Short P.Month | 785 (K) |
| EPS | -4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -70.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -1.9 |
| PEG Ratio | 0 |
| Price to Book value | -4.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|